Dermata Therapeutics (DRMA) Stock Overview

Engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. More details

DRMA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 155.23% per year

Risk Analysis

Earnings are forecast to decline by an average of 16.4% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($6M)

+ 2 more risks

DRMA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW487,274 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

487,274 investors already sharing narratives

View all narratives

Dermata Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Dermata Therapeutics
Historical stock prices
Current Share Price	US$1.34
52 Week High	US$8.00
52 Week Low	US$1.10
Beta	0.67
1 Month Change	11.67%
3 Month Change	9.84%
1 Year Change	-81.38%
3 Year Change	-99.46%
5 Year Change	n/a
Change since IPO	-99.90%

Recent updates

Seeking Alpha • Aug 15

Dermata Therapeutics Q2 GAAP EPS of -$0.24

Dermata Therapeutics press release (NASDAQ:DRMA): Q2 GAAP EPS of -$0.24 (vs. -$0.70 Y/Y). As of Jun. 30, Dermata had $10.6M in cash. Shares -4.29% AH.

Analysis Article • Nov 22

We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

	DRMA	US Biotechs	US Market
7D	0%	3.4%	-0.4%
1Y	-81.4%	37.9%	18.4%

Return vs Industry: DRMA underperformed the US Biotechs industry which returned 37.9% over the past year.

Return vs Market: DRMA underperformed the US Market which returned 18.4% over the past year.

Price Volatility

Is DRMA's price volatile compared to industry and market?
DRMA volatility
DRMA Average Weekly Movement	9.4%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: DRMA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DRMA's weekly volatility has decreased from 17% to 9% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	9	Gerry Proehl	www.dermatarx.com

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Dermata Therapeutics, Inc. Fundamentals Summary

How do Dermata Therapeutics's earnings and revenue compare to its market cap?
DRMA fundamental statistics
Market cap	US$5.63m
Earnings (TTM)	-US$7.10m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Is DRMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DRMA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$7.10m
Earnings	-US$7.10m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.77
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did DRMA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/09 22:41
End of Day Share Price	2026/07/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dermata Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anthony Vendetti	Maxim Group

Dermata Therapeutics (DRMA) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Dermata Therapeutics, Inc. Competitors

Mustang Bio

Aptevo Therapeutics

HCW Biologics

NuCana

Price History & Performance

Recent News & Updates

New major risk - Financial position

Dermata Therapeutics, Inc., Annual General Meeting, May 27, 2026

New major risk - Share price stability

New major risk - Financial position

New minor risk - Share price stability

Dermata Therapeutics, Inc. Announces Panel Grants Company’s Request for an Exception Until August 14, 2025

Recent updates

New major risk - Financial position

Dermata Therapeutics, Inc., Annual General Meeting, May 27, 2026

New major risk - Share price stability

New major risk - Financial position

New minor risk - Share price stability

Dermata Therapeutics, Inc. Announces Panel Grants Company’s Request for an Exception Until August 14, 2025

Dermata Therapeutics, Inc., Annual General Meeting, Jul 15, 2025

Dermata Therapeutics Regains Compliance with the Minimum Stockholders’ Equity Requirement and Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Financial position

Dermata Therapeutics, Inc. Announces Yymngari Phase 3 Star-1 Clinical Study Design

Dermata Therapeutics, Inc. Announces Positive Topline Results from First Pivotal Phase 3 Trial of Yymngari

Dermata Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Dermata Therapeutics, Inc. Announces Last Patient Completes Last Visit in Pivotal Xymngari Phase 3 Star-1 Clinical Trial for Acne

Dermata Therapeutics, Inc. announced that it has received $2.550008 million in funding

Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in Acne

Dermata Therapeutics, Inc. Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for Acne

New major risk - Financial position

Dermata Therapeutics, Inc. announced that it expects to receive $3.498089 million in funding

New major risk - Financial position

Dermata Therapeutics, Inc. Announces Achievement of 50% Enrollment in Pivotal Dmt310 Phase 3 Star-1 Clinical Trial for Acne

Dermata Therapeutics Regains Compliance with Listing Rule 5550(a)(4)

Dermata Therapeutics, Inc. Gets Nasdaq Extension to Regain Compliance

New major risk - Revenue and earnings growth

Dermata Therapeutics, Inc., Annual General Meeting, May 07, 2024

New major risk - Revenue and earnings growth

New major risk - Share price stability

Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols

New major risk - Share price stability

New major risk - Financial position

Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne

Dermata Therapeutics, Inc., Annual General Meeting, Aug 03, 2023

Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis

Price target decreased by 96% to US$4.00

Nasdaq Grants Dermata Therapeutics A 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Dermata Therapeutics, Inc. Announces Topline Results from Its Phase 2 Trial of Once-Weekly Topical Application of DMT310 for the Treatment of Moderate-To-Severe Rosacea

High number of new directors

Dermata Therapeutics Q2 GAAP EPS of -$0.24

Dermata Therapeutics, Inc. Receives Written Notice from the Listing Qualifications Department of Nasdaq for Compliance with the $1.00 Minimum Bid Price Requirement

Dermata Therapeutics, Inc., Annual General Meeting, Jul 11, 2022

High number of new directors

Dermata Therapeutics, Inc. Receives Correspondence from the U.S. Food and Drug Administration for Waiver Request for the Requirements to Complete a 90-Day Dermal Toxicity

Dermata Therapeutics, Inc. Submits Requests to the U.S. Food and Drug Administration for the Waiver of the Requirements to Complete A 90-Day Dermal Minipig Study and a Standard Dermal Pharmacokinetic Study

High number of new directors

We're Hopeful That Dermata Therapeutics (NASDAQ:DRMA) Will Use Its Cash Wisely

Chief Financial Officer Thomas Insley has left the company

Dermata Therapeutics, Inc. has completed an IPO in the amount of $17.999996 million.

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Dermata Therapeutics, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources